Hepatologist at the Swiss Liver Center, Bern. Interests: Cirrhosis, ALD. Travel and meeting new people. 🇵🇹🇺🇸🇨🇭
Bern, Schweiz
Joined March 2017
- Tweets542
- Following437
- Followers635
- Likes4.6K
Susana Rodrigues retweeted
#Baveno VIII consensus in portal hypertension #CSPH
Full Consensus Report now @JHepatology @EASLnews
journal-of-hepatology.eu/art…
Susana Rodrigues retweeted
Hepatology’s simplest equation:
1. 🍺 Alcohol-associated liver disease is the main killer.
2. 📈 Abstinence improves survival.
Yet addiction training is missing from the curriculum.
Addiction medicine must be core training. Lives depend on it.
Susana Rodrigues retweeted
Baveno VIII Consensus Conference provides updated guidance on advanced chronic liver disease, portal hypertension and vascular liver disease
easl.eu/news/baveno-viii-con…
Susana Rodrigues retweeted
The most important blood test in hepatology is PETH
Here is a great framework for its use, interpretation and limitations from Marina Serper @serperm in @AGA_Gastro
doi.org/10.1053/j.gastro.202…
Susana Rodrigues retweeted
It’s finally here‼️
🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖
Time to dive into the latest consensus on portal hypertension from @BavenoCoop
Enjoy! 😉
🔗 journal-of-hepatology.eu/art…
Susana Rodrigues retweeted
💉 GLP-1 RAs after liver transplantation: safe and effective?
In a multicenter study, GLP-1 RAs reduced weight, BMI & HbA1c without affecting graft function, immunosuppression levels, rejection or major adverse cardiovascular events.
🔗 doi.org/10.1097/LVT.00000000…
Susana Rodrigues retweeted
Unlike parenteral nutrition and the receipt of nothing by mouth, which impair gut health by reducing epithelial-cell proliferation, increasing apoptosis, and disrupting mucosal integrity, enteral nutrition supports gut function by enhancing tight-junction protein expression, reducing enterocyte apoptosis, preserving villous and crypt architecture, maintaining Paneth-cell function, supporting gut-associated lymphoid tissue, and helping to sustain commensal microbiota.
Learn more in “Nutrition Therapy in Critically Ill Adults,” a new review by Jayshil J. Patel, MD, and Stephen A. McClave, MD: nej.md/44m85Wt
Susana Rodrigues retweeted
📜 NITs in defining CSPH — Baveno VIII
🗣️ @RodriguesSu24 | #EASLCongress
Key messages:
🔬 LSM + ANTICIPATE → mainstay of CSPH diagnosis ⚠️ Repeat NITs every 12 m — most recent value wins
💡 SSM + biomarkers reduce the CSPH grey zone
🚀 Future: AI-driven multimodal assessment
Susana Rodrigues retweeted
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO
ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.
ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
Susana Rodrigues retweeted
💙 Remembering Jaume Bosch | #EASLCongress
🗣️ Beautiful tribute by @ggarciatsao
🔬 One of the Baveno founders & a giant of PH
🌍 Mentor, collaborator & citizen of the world
💡 "Your legacy lives on — in the questions we ask, in the way we work" — @JSGracia, Baveno VIII
Susana Rodrigues retweeted
#EASLCongress in Barcelona = @BavenoCoop field
▪️BAVENO hub — Wed 27 | 16:15–16:45
▪️ EASL/Baveno Symposium — Thu 28 | 08:30–09:45
▪️ Symposium: Crossing the point of no return — Fri 29 | 15:00–16:00
▪️ + SLC on variceal🩸, liver haemodynamics & EUS-PPG
Susana Rodrigues retweeted
📑 The impact of #sarcopenia 💪🏾 and #frailty on decompensation in compensated cirrhosis: A systematic review‼️
⬆️ Prevalence of Sarcopenia
But, most studies with 🚫 increased risk of first decompensation❕
journals.lww.com/hepcomm/ful…
Susana Rodrigues retweeted
First double-blind, placebo-controlled RCT in @TheLancet showing that SEMAGLUTIDE reduces ALCOHOL intake in people with BMI >25.
Potentially practice-changing.
shorturl.at/B45aU
Susana Rodrigues retweeted
🟣EASL position paper on palliative care in advanced chronic liver disease
🔓#OpenAccess at👉jhep-reports.eu/article/S258…
#LiverDisease #LiverX
#LiverTwitter #LiverHealth
Susana Rodrigues retweeted
Recompensation is reshaping how we understand cirrhosis, but key gaps remain.
Join @salvatore_piano, @elizabeth_verna, and @DrLoomba in two weeks to explore how etiological control enables recompensation, what defines it clinically, and how outcomes may shift for patients. Save your seat: bit.ly/4sclXfg
Susana Rodrigues retweeted
Interested in #Recompensation?
Join the upcoming @AASLDtweets webinar on #Recompensation by @salvatore_piano, @elizabeth_verna @DrLoomba
👉shorturl.at/TxuDj
#LiverX #PortalHTNSIG #cirrhosis
🤖 Made with AI
The natural history of advanced chronic liver disease is being rewritten📖Learn about recompensation at this @AASLDtweets webinar — moderated by #AnahitaRabiee with a stellar panel. April 28 🗓️ aasld.org/webinar-recompensa…
Susana Rodrigues retweeted
This Wednesday, a new Talk Liver to Me podcast episode awaits you!
This time, experts @tom_marjot, @MattiasMandorf1 & Cristina Ripoll break down the key takeaways from the Baveno VIII meeting. What’s changed in portal hypertension management, what reached consensus, and what’s still debated?
Read more: easl.eu/event/baveno-viii-ta…
#LiverTwitter #LiverX
During the inspiring @BavenoCoop VIII, it was great to meet up with some of the @AASLDtweets portal hypertension SIG VIII committee members. @Yujun__Wong
@VirginiaHdezGea @NorthupHepTXP #AnahitaRabiee. Congrats to Anahita for your prize!
